Dr. Devi Sengupta

Dr. Anna Durbin is an associate professor at the Johns Hopkins University School of Medicine. Her area of clinical expertise is infectious disease. Dr. Durbin earned her M.D. from Wayne State University School of Medicine. She completed her residency and performed a fellowship in infectious diseases at Detroit Medical Center. She has expertise in the evaluation of live attenuated flavivirus vaccines, primary dengue and West Nile virus vaccines, and the early evaluation of malaria vaccines. She has served on national and international advisory boards and committees related to dengue and malaria vaccine safety. An important research interest of hers is studying the immunopathogenesis of dengue infection and disease. In addition to her clinical studies, her laboratory is also developing an animal model of dengue using rhesus macaques. Dr. Durbin is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Dengue Fever, Viral Hemorrhagic Fever, Arbovirosis, and Yellow Fever. Dr. Durbin is board certified in American Board Of Internal Medicine. Dr. Durbin is currently accepting new patients.

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine. Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017). Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries. Dr. Sulkowski is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, HIV/AIDS, and Hepatitis B. Dr. Sulkowski is board certified in American Board Of Internal Medicine. Dr. Sulkowski is currently accepting new patients.

Dr. Kelly Gebo is a graduate of The Johns Hopkins University School of Medicine. She also earned an MPH in Epidemiology from The Johns Hopkins Bloomberg School of Public Health. She completed residency training in Internal Medicine at The Johns Hopkins Hospital followed by an infectious diseases fellowship and two additional years of fellowship training as a Robert Wood Johnson Clinical Scholar, also at Hopkins. Her clinical and research interests include clinical outcomes and healthcare utilization research within infectious diseases. She was Director of the JHU Public Health Studies Program between the Krieger School for Arts and Sciences and the Bloomberg School for Public Health, was an American Council of Education Fellow (hosted at the University of Pennsylvania) and was the inaugural Vice Provost for Education at Johns Hopkins. She was on sabbatical at Stanford University School of Medicine 2019-20 and served as the Chief Medical and Scientific Officer for the All of Us Research Program 2018-2020. She currently serves as the director of the Johns Hopkins Clinical Research Scholars Program and is Deputy Director of the Johns Hopkins Institute for Clinical and Translational Research. She has mentored undergraduate, public health and medical students, trainees, and junior faculty on infectious diseases and health services projects. She has authored or co-authored numerous chapters and over 250 papers. She is a member of the American Society of Clinical Investigation and has been awarded the David Levine Prize for mentoring at Johns Hopkins. LinkedIn https://www.linkedin.com/in/kelly-gebo-13377811/. Dr. Gebo is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex. Dr. Gebo is board certified in American Board Of Internal Medicine. Dr. Gebo is currently accepting new patients.